According to analysts predictions, the value of the monoclonal antibody market in 2015 will be 60 billion USD, reaching over 75 billion USD in 2025. Sales of the humanized monoclonal antibodies are increasing twice as fast as other biotechnological drugs.
The world market of two monoclonal antibody drugs, on which Mabion is focused now (MabionCD20 and MabionHER2), has already reached 10 billion USD annually. Thanks to special technology developed, Mabion expects higher monoclonal antibody productivity than competitive companies, making the drugs 30-40% cheaper. Currently, yearly therapy cost for one breast cancer patient is around 50 thousand USD and around 35 thousand USD for blood cancers.